Advaxis cancer drug gets Orphan designation

|About: Advaxis Inc. (ADXS)|By:, SA News Editor

The FDA designates Advaxis' (ADXS +6.8%) ADXS-cHER2 an Orphan Drug for the treatment of osteosarcoma. The drug is an immunotherapy that targets the HER2 receptor which is overexpressed in certain cancers. The company plans to initiate a clinical development program in pediatric osteosarcoma, a rare cancer affecting ~400 children and teens in the U.S. each year.